title: Vaptans and hyponatremia in critical patients.
abstract: Hyponatremia is the most frequent fluid and electrolyte disorder in hospitalized patients (20%), particularly in ICU, associated with an increase in morbility and mortality. While hypovolaemic hyponatremia needs to be corrected with the replacement of the lost extracellular fluid by isotonic saline, euvolaemic (SIADH) and hypervolaemic hyponatremia (oedematous states like decompensated heart failure, liver cirrhosis, i.e.) are treated by restriction of fluid intake, loop diuretics and hypertonic saline. A novel approach consists in use of vaptans, non-peptide arginine vasopressin (AVP) receptor antagonists. Vaptans cause "aquaresis", which results in the correction of plasma osmolality and serum sodium levels, without activation of the renin-angiotensin-aldosterone system or changes in blood pressure and renal function. In this paper we critically reviewed the results of the available randomized controlled critical trials, discussing the effectiveness and safety of vaptans in treating hypervolaemic and euvolaemic hyponatremia in critical patients.
authors.affiliation: Department of Anesthesia and Intensive Care, Federico II University, Napoli, Italy.
authors.forename: David
authors.initials: D
authors.lastname: D'Auria
authors.forename: Geremia Zito
authors.initials: GZ
authors.lastname: Marinosci
authors.forename: Giuseppe
authors.initials: G
authors.lastname: De Benedictis
authors.forename: Ornella
authors.initials: O
authors.lastname: Piazza
keywords: AVP receptor antagonists; hyponatremia; vaptans; vasopressin
references.citation: N Engl J Med. 2006 Nov 16;355(20):2099-112
references.pmid: 17105757
references.citation: Nephrol Dial Transplant. 2006 Jan;21(1):70-6
references.pmid: 16141458
references.citation: Am J Med Sci. 2009 Jan;337(1):28-36
references.pmid: 19057376
references.citation: Am J Cardiol. 2006 Apr 1;97(7):1064-7
references.pmid: 16563917
references.citation: JAMA. 2007 Mar 28;297(12):1319-31
references.pmid: 17384437
references.citation: Adv Exp Med Biol. 1998;449:439-43
references.pmid: 10026835
references.citation: Neurocrit Care. 2011 Jun;14(3):354-60
references.pmid: 21409494
references.citation: Clin Chim Acta. 2003 Nov;337(1-2):169-72
references.pmid: 14568195
references.citation: Am J Nephrol. 2005 May-Jun;25(3):240-9
references.pmid: 15914973
references.citation: Am J Nephrol. 2007;27(5):447-57
references.pmid: 17664863
references.citation: N Engl J Med. 2000 May 25;342(21):1581-9
references.pmid: 10824078
references.citation: Eur J Heart Fail. 2011 Mar;13(3):327-36
references.pmid: 21199833
references.citation: N Engl J Med. 2005 May 5;352(18):1884-90
references.pmid: 15872203
references.citation: Physiol Rev. 2002 Jan;82(1):205-44
references.pmid: 11773613
references.citation: Hepatology. 2003 Jan;37(1):182-91
references.pmid: 12500203
references.citation: Endocrinol Metab Clin North Am. 2003 Jun;32(2):459-81, vii
references.pmid: 12800541
references.citation: J Hepatol. 2010 Aug;53(2):283-90
references.pmid: 20541828
references.citation: Circulation. 2003 Jun 3;107(21):2690-6
references.pmid: 12742979
references.citation: Circulation. 2001 Nov 13;104(20):2417-23
references.pmid: 11705818
references.citation: J Am Soc Nephrol. 2007 Feb;18(2):606-12
references.pmid: 17229917
references.citation: Drug Des Devel Ther. 2009 Dec 29;3:253-68
references.pmid: 20054444
references.citation: Hepatology. 2008 Jul;48(1):204-13
references.pmid: 18508290
references.citation: Gastroenterology. 2003 Apr;124(4):933-9
references.pmid: 12671890
references.citation: J Neuroendocrinol. 1991 Jun 1;3(3):237-47
references.pmid: 19215459
references.citation: Nephron Clin Pract. 2011;119(1):c62-73; discussion c73
references.pmid: 21677440
references.citation: Br J Pharmacol. 1992 Apr;105(4):787-91
references.pmid: 1387020
references.citation: J Clin Endocrinol Metab. 2006 Jun;91(6):2145-52
references.pmid: 16522696
references.citation: J Pharmacol Exp Ther. 1997 Jul;282(1):301-8
references.pmid: 9223568
references.citation: Am J Health Syst Pharm. 2011 May 1;68(9):818-27
references.pmid: 21515866
references.citation: Am J Med. 1980 Jul;69(1):99-106
references.pmid: 7386514
references.citation: CMAJ. 2004 Feb 3;170(3):365-9
references.pmid: 14757675
references.citation: Am Fam Physician. 2004 May 15;69(10):2387-94
references.pmid: 15168958
references.citation: J Clin Invest. 1996 Dec 15;98(12):2729-38
references.pmid: 8981918
references.citation: Adv Exp Med Biol. 1998;449:251-76
references.pmid: 10026814
references.citation: J Am Soc Nephrol. 2008 Jun;19(6):1054-8
references.pmid: 18337478
references.citation: Neurocrit Care. 2010 Aug;13(1):57-61
references.pmid: 20568023
references.citation: Clin Transl Sci. 2010 Oct;3(5):249-53
references.pmid: 20973922
references.citation: Arch Intern Med. 2007 Oct 8;167(18):1998-2005
references.pmid: 17923601
references.citation: J Pharmacol Exp Ther. 1998 Dec;287(3):860-7
references.pmid: 9864265
references.citation: Am J Nephrol. 2006;26(4):348-55
references.pmid: 16837788
references.citation: Clin J Am Soc Nephrol. 2006 Nov;1(6):1154-60
references.pmid: 17699341
references.citation: Clin Nephrol. 1996 Sep;46(3):149-69
references.pmid: 8879850